广发证券近期发布研报称，公司核心品种陆续获批上市有望助力产品销售快速放量，全球权益管线在临床阶段展现治疗潜力推动公司发展进入新阶段，该行看好公司商业化和创新研发持续向好。预计公司24-26 年分别实现收入3.87、5.61 和8.56 亿美元，采取风险调整DCF法得到公司合理价值33.70 港元/股，首次覆盖，给予“买入”评级。Zaiding Pharmaceutical (09688) rose more than 5%. As of press release, it was up 5.01% to HK$20.35, with a turnover of HK$51.4273 million.
The Zhitong Finance App learned that Zaiding Pharmaceutical (09688) rose by more than 5%. As of press release, it had risen 5.01% to HK$20.35, with a turnover of HK$51.4273 million.
According to the news, CITIC Securities pointed out that Zaiding Pharmaceutical has now built up a promising product pipeline, commercialization is progressing smoothly, and operating income is growing rapidly, and it is expected to reverse losses. Many products in the company's pipeline have the potential to become “blockbuster” drugs. The peak sales of single products is expected to exceed 5 billion yuan, and they are all in the early stages of commercialization. There is strong certainty that performance will grow rapidly in the next 2-3 years. The company has gradually established self-research capabilities, and is developing a wealth of products in the early stages, continuously empowering long-term development.
GF Securities recently released a research report saying that the company's core products have been approved and listed one after another, which is expected to help product sales expand rapidly. The global equity pipeline shows therapeutic potential in the clinical phase to drive the company's development into a new stage. The bank is optimistic that the company's commercialization and innovative research and development will continue to improve. The company is expected to achieve revenue of US$387, 5.61 and US$856 million in 24-26, respectively. Using the risk-adjusted DCF method, the company obtained a reasonable value of HK$33.70 per share, which was covered for the first time, giving it a “buy” rating.
